Skip to main content

Table 1 French guidelines for cART initiation from 2000 to 2010

From: The effect of adherence to guidelines for initial antiretroviral therapy on 1-year outcomes: a French cohort study

a "when-to-start" guidelines

 

2000

2002

2004

2006

2008

2010

CDC B-C

Rec.

Rec.

Rec.

Rec.

Rec.

Rec.

CD4 < 200/mm3

Rec.

Rec.

Rec.

Rec.

Rec.

Rec.

CD4 < 15%

Rec.

Rec.

Rec.

Rec.

Rec.

Rec.

CD4 200-349/mm3

Rec.

Opt. (1)

Rec.

Rec.

Rec.

Rec.

CD4 350-500/mm3

 

NR

Opt. (1)

Opt. (1)

Opt. (2)

Rec.

CD4 > 500/mm3

 

NR

NR

NR

NR

Opt. (3)

b "what-to-start" guidelines

 

2000

2002

2004

2006

2008

2010

NRTIs Backbone

      

ZDV + ddI

Pref.

Pref.

Alt.

Pref.

NR

NR

ZDV +3TC

Pref.

Pref.

Pref.

Pref.

Alt.

Alt.

d4T + ddI

Pref.

NR

NR

NR

NR

NR

d4T +3TC

Pref.

Pref.

Alt.

NR

NR

NR

ZDV + FTC

 

Alt.

Pref.

Pref.

Alt.

Alt.

TDF +3TC

 

Alt.

Pref.

Pref.

Pref.

Alt.

TDF + FTC

 

Alt.

Pref.

Pref.

Pref.

Pref.

ddI +3TC

 

Alt.

Pref.

Pref.

Pref.

NR

ddI + FTC

 

Alt.

Pref.

Pref.

Pref.

NR

ABC +3TC

 

Alt.

Pref.

Pref.

Pref.

Pref.

ABC + FTC

 

Alt.

Pref.

Pref.

Pref.

Alt.

ddI + TDF

 

Alt.

Alt.

NR

NR

NR

3 NRTIs combinations

      

ABC +3TC + ddI

 

Alt.

NR

NR

NR

NR

ABC +3TC + d4T

 

Alt.

NR

NR

NR

NR

ZDV +3TC + ddI

 

Alt.

NR

NR

NR

NR

ABC +3TC + TDF

 

Alt.

NR

NR

NR

NR

TDF + ddI +3TC

 

Alt.

NR

NR

NR

NR

ZDV +3TC + ABC

Pref.

Pref.

Alt. (1)

Alt. (1)

NR

NR

Other 3 NRTI combinations

 

Alt.

NR

NR

NR

NR

Unboosted PIs

      

RTV

Pref.

NR

NR

NR

NR

NR

IDV

Pref.

NR

NR

NR

NR

NR

NFV

Pref.

Pref.

Alt.

NR

  

Boosted PIs

      

APVr

Alt.

Alt.

    

SQVr

Pref.

Pref.

Pref.

Pref.

Alt.

Alt.

IDVr

Alt.

Pref.

Pref.

Alt.

Alt.

Alt.

LPVr

Alt.

Pref.

Pref.

Pref.

Pref.

Pref.

fAPVr

  

Pref.

Pref.

Pref.

Alt.

ATVr

   

Alt.

Pref.

Pref.

DRVr

   

NR

Alt.

Pref.

NNRTIs

      

EFV

Pref.

Pref.

Pref.

Pref.

Pref.

Pref.

NVP

Pref.

Pref.

Pref.

Alt.

Alt.

Alt.

Integrase Inhibitor

      

RAL

     

Alt.

Antiretroviral combinations

      

NNRTI + PI (boosted or not)

   

NR

NR

NR

2 NRTIs +1 NNRTI

Pref.

Pref.

Pref.

Pref.

Pref.

Pref.

2 NRTIs +1 PI

Pref.

Pref.

Alt.

NR

NR

NR

2 NRTIs +1 boosted PI

Pref.

Pref.

Pref.

Pref.

Pref.

Pref.

Boosted PI monotherapy

   

NR

NR

NR

  1. Abbreviations: Rec ART recommended, Opt ART optional, NR ART Not recommended; (1), if HIV-RNA >105 log copies/ml; (2), if HIV-RNA >105 log copies/ml >50 years, HBV/HCV coinfection or high cardiovascular risk; (3), if HIV-RNA >105 log copies/ml, >50 years, HBV/HCV coinfection, high cardiovascular risk or treatment as prevention.
  2. Abbreviations: ZDV zidovudine, ddI didanosine, 3TC lamivudine, d4T stavudine, FTC emtricitabine, TDF tenofovir, ABC abacavir, NRTI nucleoside/nucleotide reverse transcriptase inhibitors, PI protease inhibitor, RTV ritonavir, IDV indinavir, NFV nelfinavir, APVr boosted amprenavir, SQVr boosted saquinavir, IDVr boosted indinavir, LPVr boosted lopinavir, fAPVr boosted fosamprenavir, ATVr boosted atazanavir, DRVr boosted darunavir, NNRTI non-nucleoside reverse transcriptase inhibitors, EFV efavirenz, NVP nevirapine, RAL raltegravir, Pref preferred, Alt alternative, NR Not recommended; (1), if HIV-RNA <105 log copies/ml.